Geode Capital Management
PTGX icon

Geode Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Geode Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213M Buy
1,741,209
+71,838
+4% +$7.5M 0.01% 773
2026
Q1 		$176M Buy
1,669,371
+216,443
+15% +$19.2M 0.01% 787
2025
Q4 		$127M Buy
1,452,928
+36,282
+3% +$2.97M 0.01% 926
2025
Q3 		$94.1M Sell
1,416,646
-27,584
-2% -$1.57M 0.01% 1109
2025
Q2 		$79.8M Buy
1,444,230
+20,671
+1% +$992K 0.01% 1156
2025
Q1 		$68.9M Buy
1,423,559
+46,496
+3% +$1.95M 0.01% 1187
2024
Q4 		$53.2M Buy
1,377,063
+2,366
+0.2% +$103K ﹤0.01% 1391
2024
Q3 		$61.9M Buy
1,374,697
+3,528
+0.3% +$143K 0.01% 1295
2024
Q2 		$47.5M Buy
1,371,169
+77,430
+6% +$2.27M ﹤0.01% 1390
2024
Q1 		$37.4M Buy
1,293,739
+45,455
+4% +$1.24M ﹤0.01% 1552
2023
Q4 		$28.6M Buy
1,248,284
+67,028
+6% +$1.17M ﹤0.01% 1699
2023
Q3 		$19.7M Buy
1,181,256
+104,072
+10% +$2.02M ﹤0.01% 1834
2023
Q2 		$29.8M Buy
1,077,184
+151,191
+16% +$3.78M ﹤0.01% 1593
2023
Q1 		$21.3M Buy
925,993
+46,102
+5% +$774K ﹤0.01% 1758
2022
Q4 		$9.6M Buy
879,891
+52,435
+6% +$442K ﹤0.01% 2290
2022
Q3 		$6.97M Buy
827,456
+5,535
+0.7% +$52.4K ﹤0.01% 2480
2022
Q2 		$6.5M Sell
821,921
-11,000
-1% -$133K ﹤0.01% 2550
2022
Q1 		$19.7M Buy
832,921
+54,840
+7% +$1.55M ﹤0.01% 1916
2021
Q4 		$26.6M Buy
778,081
+49,151
+7% +$1.55M ﹤0.01% 1763
2021
Q3 		$12.9M Buy
728,930
+15,092
+2% +$643K ﹤0.01% 2276
2021
Q2 		$32M Buy
713,838
+68,159
+11% +$2.25M ﹤0.01% 1664
2021
Q1 		$16.7M Buy
645,679
+137,378
+27% +$3.48M ﹤0.01% 1990
2020
Q4 		$10.2M Buy
508,301
+69,187
+16% +$1.49M ﹤0.01% 2167
2020
Q3 		$8.58M Buy
439,114
+70,744
+19% +$1.33M ﹤0.01% 2044
2020
Q2 		$6.5M Buy
368,370
+74,774
+25% +$938K ﹤0.01% 2185
2020
Q1 		$2.07M Buy
293,596
+22,998
+8% +$172K ﹤0.01% 2652
2019
Q4 		$1.91M Buy
270,598
+9,425
+4% +$93.6K ﹤0.01% 3028
2019
Q3 		$3.14M Buy
261,173
+57,322
+28% +$722K ﹤0.01% 2662
2019
Q2 		$2.47M Buy
203,851
+71,207
+54% +$787K ﹤0.01% 2813
2019
Q1 		$1.67M Buy
132,644
+14,947
+13% +$132K ﹤0.01% 2958
2018
Q4 		$792K Sell
117,697
-128
-0.1% -$1.01K ﹤0.01% 3201
2018
Q3 		$1.21M Sell
117,825
-8,202
-7% -$70.6K ﹤0.01% 3137
2018
Q2 		$846K Sell
126,027
-15,657
-11% -$120K ﹤0.01% 3251
2018
Q1 		$1.22M Buy
141,684
+1,707
+1% +$32.1K ﹤0.01% 3033
2017
Q4 		$2.91M Buy
139,977
+27,135
+24% +$481K ﹤0.01% 2539
2017
Q3 		$1.99M Buy
112,842
+5,962
+6% +$82.6K ﹤0.01% 2753
2017
Q2 		$1.21M Buy
106,880
+5,662
+6% +$60.5K ﹤0.01% 3021
2017
Q1 		$1.3M Buy
101,218
+1,850
+2% +$29.8K ﹤0.01% 2892
2016
Q4 		$2.19M Buy
99,368
+6,548
+7% +$146K ﹤0.01% 2585
2016
Q3 		$1.96M Buy
+92,820
New +$1.27M ﹤0.01% 2574

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management's PTGX Position: Q2 2026 in Review

Geode Capital Management increased its Protagonist Therapeutics (PTGX) stake by 4.3% in Q2 2026, buying an estimated $7.5M and bringing the position to 1,741,209 shares worth $213M. The position accounts for 0.01% of the portfolio, ranked #773.

Geode Capital Management first reported a position in PTGX in Q3 2016 and has held it in 40 quarters since. 341 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Geode Capital Management held 1,741,209 shares of Protagonist Therapeutics worth $213M as of Q2 2026.
  • Geode Capital Management bought 71,838 Protagonist Therapeutics shares in Q2 2026, an estimated $7.5M.
  • Protagonist Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #773 holding.
  • Geode Capital Management first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 40 quarters since.
  • 341 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.